Treatment of chronic hepatitis B with Telbivudine alone or in combination with nucleotide analogues

Introduction: Telbivudine is a new generation nucleoside analogue which was recently approved for treatment of chronic hepatitis B (CHB). Other than in clinical trials there has been only limited experience with this drug in clinical practice. Patients and study design: A total of 39 patients with CHB received Telbivudine as first line therapy (n=29) or as an add-on to a previously failed therapy with Adefovir (n=10). Patients who did not show virological response to the initial treatment with Telbivudine after 24 weeks were addionally treated with Tenofovir. Virological resistance was analyzed retrospectively.…